In detecting PCa, PSA testing plays a pivotal role in the detection of a localized disease that accounts for over 90% of newly registered cases in developed countries because non-metastatic PCa does not manifest specific symptoms except vague male lower urinary tract symptoms (LUTSs) that originate more frequently from concomitant benign prostate enlargement. Here, KLK3 is linked to posterior cortical atrophy.